SOCS1 regulates senescence and ferroptosis by modulating the expression of p53 target genes

Aging

Volumn 9, Issue 10, 2017, Pages 2134-2159

  Saint Germain, Emmanuelle ^a   Mignacca, Lian ^a   Vernier, Mathieu ^b   Bobbala, Diwakar ^c   Ilangumaran, Subburaj ^c   Ferbeyre, Gerardo ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Ferroptosis; KAP1; Senescence; Suppressor of cytokine signaling; Tumor suppressor

Indexed keywords

PROTEIN P53; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TP53 PROTEIN, HUMAN;

CELL AGING; CELL LINE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; CELLULAR SENESCENCE; GENE EXPRESSION REGULATION; HUMANS; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85032735852     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101306     Document Type: Article

References (53)

1. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysisof cancer genes across 21 tumour types. Nature.2014; 505:495-501. https://doi.org/10.1038/nature12912
2. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell.2006; 124:207-19. https://doi.org/10.1016/j.cell.2005.10.043
3. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinctregulatory mechanisms and functions for p53-activated and p53-repressed DNA damage responsegenes in embryonic stem cells. Mol Cell. 2012;46:30-42.https://doi.org/10.1016/j.molcel.2012.01.020
4. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, BaerR, Gu W. Ferroptosis as a p53-mediated activityduring tumour suppression. Nature. 2015; 520:57-62.https://doi.org/10.1038/nature14344
5. Fischer M, Grossmann P, Padi M, DeCaprio JA.Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle generegulatory networks. Nucleic Acids Res. 2016;44:6070-86. https://doi.org/10.1093/nar/gkw523
6. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD. Distinct p53transcriptional programs dictate acute DNA-damageresponses and tumor suppression. Cell. 2011;145:571-83. https://doi.org/10.1016/j.cell.2011.03.035
7. Valente LJ, Grabow S, Vandenberg CJ, Strasser A, Janic A. Combined loss of PUMA and p21 acceleratesc-MYC-driven lymphoma development considerablyless than loss of one allele of p53. Oncogene. 2016;35:3866-71. https://doi.org/10.1038/onc.2015.457
8. Kirschner K, Samarajiwa SA, Cairns JM, Menon S, Pérez-Mancera PA, Tomimatsu K, Bermejo-RodriguezC, Ito Y, Chandra T, Narita M, Lyons SK, Lynch AG, Kimura H, et al. Phenotype specific analyses revealdistinct regulatory mechanism for chronicallyactivated p53. PLoS Genet. 2015; 11:e1005053.https://doi.org/10.1371/journal.pgen.1005053
9. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM inresponse to DNA damage. Science. 1998; 281:1674-77.https://doi.org/10.1126/science.281.5383.1674
10. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damageactivates p53 through a phosphorylation-acetylationcascade. Genes Dev. 1998; 12:2831-41.https://doi.org/10.1101/gad.12.18.2831
11. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, OrlowI, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4atumor suppressor gene product, p19Arf, interactswith MDM2 and neutralizes MDM2's inhibition ofp53. Cell. 1998; 92:713-23. https://doi.org/10.1016/S0092-8674(00)81400-2
12. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stabilityby sequestering Mdm2 to the nucleolus. Nat CellBiol. 2004; 6:665-72. https://doi.org/10.1038/ncb1147
13. Donati G, Peddigari S, Mercer CA, Thomas G. 5Sribosomal RNA is an essential component of anascent ribosomal precursor complex that regulatesthe Hdm2-p53 checkpoint. Cell Reports. 2013; 4:87-98.https://doi.org/10.1016/j.celrep.2013.05.045
14. Calabrese V, Mallette FA, Deschênes-Simard X, Ramanathan S, Gagnon J, Moores A, Ilangumaran S, Ferbeyre G. SOCS1 links cytokine signaling to p53and senescence. Mol Cell. 2009; 36:754-67.https://doi.org/10.1016/j.molcel.2009.09.044
15. Mallette FA, Calabrese V, Ilangumaran S, Ferbeyre G.SOCS1, a novel interaction partner of p53 controllingoncogene-induced senescence. Aging (Albany NY).2010; 2:445-52. https://doi.org/10.18632/aging.100163
16. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG.SOCS-1, a negative regulator of the JAK/STATpathway, is silenced by methylation in humanhepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001; 28:29-35.https://doi.org/10.1038/ng0501-29
17. Khoo KH, Verma CS, Lane DP. Drugging the p53pathway: understanding the route to clinicalefficacy. Nat Rev Drug Discov. 2014; 13:217-36.https://doi.org/10.1038/nrd4288
18. Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, Khanna KK. BRCA1-BARD1 complexesare required for p53Ser-15 phosphorylation and aG1/S arrest following ionizing radiation-induced DNAdamage. J Biol Chem. 2004; 279:31251-58.https://doi.org/10.1074/jbc.M405372200
19. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancergrowth involves suppression of angiogenesis.Oncogene. 2007; 26:1811-19. https://doi.org/10.1038/sj.onc.1209977
20. Magnon C, Galaup A, Mullan B, Rouffiac V, BouquetC, Bidart JM, Griscelli F, Opolon P, Perricaudet M.Canstatin acts on endothelial and tumor cells viamitochondrial damage initiated through interactionwith alphavbeta3 and alphavbeta5 integrins. CancerRes. 2005; 65:4353-61. https://doi.org/10.1158/0008-5472.CAN-04-3536
21. Yeh JR, Mohan R, Crews CM. The antiangiogenicagent TNP-470 requires p53 and p21CIP/WAF forendothelial cell growth arrest. Proc Natl Acad SciUSA. 2000; 97:12782-87. https://doi.org/10.1073/pnas.97.23.12782
22. Assadian S, El-Assaad W, Wang XQ, Gannon PO, Barrès V, Latour M, Mes-Masson AM, Saad F, Sado Y, Dostie J, Teodoro JG. p53 inhibits angiogenesis byinducing the production of Arresten. Cancer Res.2012; 72:1270-79. https://doi.org/10.1158/0008-5472.CAN-11-2348
23. Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, Kapralov AA, Amoscato AA, Jiang J, et al. Oxidized arachidonic andadrenic PEs navigate cells to ferroptosis. Nat ChemBiol. 2017; 13:81-90. https://doi.org/10.1038/nchembio.2238
24. Ou Y, Wang SJ, Li D, Chu B, Gu W. Activation of SAT1engages polyamine metabolism with p53-mediatedferroptotic responses. Proc Natl Acad Sci USA. 2016;113:E6806-12.https://doi.org/10.1073/pnas.1607152113
25. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW.Dissecting the unique role of the retinoblastomatumor suppressor during cellular senescence. CancerCell. 2010; 17:376-87. https://doi.org/10.1016/j.ccr.2010.01.023
26. Vernier M, Bourdeau V, Gaumont-Leclerc MF, Moiseeva O, Bégin V, Saad F, Mes-Masson AM, Ferbeyre G. Regulation of E2Fs and senescence byPML nuclear bodies. Genes Dev. 2011; 25:41-50.https://doi.org/10.1101/gad.1975111
27. Sinha VC, Qin L, Li Y. A p53/ARF-dependentanticancer barrier activates senescence and blockstumorigenesis without impacting apoptosis. MolCancer Res. 2015; 13:231-38. https://doi.org/10.1158/1541-7786.MCR-14-0481-T
28. Jiang L, Hickman JH, Wang SJ, Gu W. Dynamic rolesof p53-mediated metabolic activities in ROS-inducedstress responses. Cell Cycle. 2015; 14:2881-85.https://doi.org/10.1080/15384101.2015.1068479
29. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, CornishVW, et al. Regulation of ferroptotic cancer cell deathby GPX4. Cell. 2014; 156:317-31. https://doi.org/10.1016/j.cell.2013.12.010
30. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. TheDNA damage signaling pathway is a critical mediatorof oncogene-induced senescence. Genes Dev. 2007;21:43-48. https://doi.org/10.1101/gad.1487307
31. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, NiforouK, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, et al. Oncogene-induced senescence is part of thetumorigenesis barrier imposed by DNA damagecheckpoints. Nature. 2006; 444:633-37. https://doi.org/10.1038/nature05268
32. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, NuciforoPG, Bensimon A, Maestro R, Pelicci PG, d'Adda diFagagna F. Oncogene-induced senescence is a DNAdamage response triggered by DNA hyper-replication. Nature. 2006; 444:638-42. https://doi.org/10.1038/nature05327
33. Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, VancurovaM, Barath P, Bartek J, Hodny Z. Regulation of thePML tumor suppressor in drug-induced senescenceof human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. 2010; 9:3085-99.https://doi.org/10.4161/cc.9.15.12521
34. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine signaling(SOCS) proteins and JAK/STAT pathways: regulationof T-cell inflammation by SOCS1 and SOCS3.Arterioscler Thromb Vasc Biol. 2011; 31:980-85. https://doi.org/10.1161/ATVBAHA.110.207464
35. Bakkenist CJ, Beumer JH, Schmitz JC. ATM serine-1981 phosphorylation is a plausible biomarker. CellCycle. 2015; 14:3207-08. https://doi.org/10.1080/15384101.2015.1084205
36. Al Rashid ST, Dellaire G, Cuddihy A, Jalali F, Vaid M, Coackley C, Folkard M, Xu Y, Chen BP, Chen DJ, LilgeL, Prise KM, Bazett Jones DP, Bristow RG. Evidencefor the direct binding of phosphorylated p53 to sitesof DNA breaks in vivo. Cancer Res. 2005; 65:10810-21.https://doi.org/10.1158/0008-5472.CAN-05-0729
37. Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, Wynford-Thomas D. Posttranslationalmodifications of p53 in replicative senescenceoverlapping but distinct from those induced by DNAdamage. Mol Cell Biol. 2000; 20:2803-08. https://doi.org/10.1128/MCB.20.8.2803-2808.2000
38. Zhang XP, Liu F, Wang W. Two-phase dynamics ofp53 in the DNA damage response. Proc Natl Acad SciUSA. 2011; 108:8990-95. https://doi.org/10.1073/pnas.1100600108
39. Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ 3rd, Chen J. MDM2 interaction withnuclear corepressor KAP1 contributes to p53inactivation. EMBO J. 2005; 24:3279-90. https://doi.org/10.1038/sj.emboj.7600791
40. Xue W, Zender L, Miething C, Dickins RA, HernandoE, Krizhanovsky V, Cordon-Cardo C, Lowe SW.Senescence and tumour clearance is triggered byp53 restoration in murine liver carcinomas. Nature.2007; 445:656-60. https://doi.org/10.1038/nature05529
41. Bouamar H, Jiang D, Wang L, Lin AP, Ortega M, Aguiar RC. MicroRNA 155 control of p53 activity iscontext dependent and mediated by Aicda andSocs1. Mol Cell Biol. 2015; 35:1329-40. https://doi.org/10.1128/MCB.01446-14
42. Mignacca L, Saint-Germain E, Benoit A, Bourdeau V, Moro A, Ferbeyre G. Sponges against miR-19 andmiR-155 reactivate the p53-Socs1 axis inhematopoietic cancers. Cytokine. 2016; 82:80-86.https://doi.org/10.1016/j.cyto.2016.01.015
43. Ron D, Habener JF. CHOP, a novel developmentallyregulated nuclear protein that dimerizes withtranscription factors C/EBP and LAP and functions asa dominant-negative inhibitor of gene transcription. Genes Dev. 1992; 6:439-53. https://doi.org/10.1101/gad.6.3.439
44. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, BrownC, Popov N, Takatsu Y, Melamed J, d'Adda diFagagna F, et al. Chemokine signaling via the CXCR2receptor reinforces senescence. Cell. 2008;133:1006-18.https://doi.org/10.1016/j.cell.2008.03.038
45. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayedby an interleukin-dependent inflammatory network.Cell. 2008; 133:1019-31. https://doi.org/10.1016/j.cell.2008.03.039
46. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H. Smad-dependent GADD45beta expressionmediates delayed activation of p38 MAP kinase byTGF-beta. EMBO J. 2002; 21:6473-82. https://doi.org/10.1093/emboj/cdf643
47. Willers H, McCarthy EE, Wu B, Wunsch H, Tang W, Taghian DG, Xia F, Powell SN. Dissociation of p53-mediated suppression of homologous recombinationfrom G1/S cell cycle checkpoint control. Oncogene.2000; 19:632-39. https://doi.org/10.1038/sj.onc.1203142
48. Dudenhöffer C, Rohaly G, Will K, Deppert W, Wiesmüller L. Specific mismatch recognition inheteroduplex intermediates by p53 suggests a role infidelity control of homologous recombination. MolCell Biol. 1998; 18:5332-42. https://doi.org/10.1128/MCB.18.9.5332
49. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic rasand promotes premature senescence. Genes Dev.2000; 14:2015-27.
50. Mallette FA, Gaumont-Leclerc MF, Huot G, FerbeyreG.Myc down-regulation as a mechanism to activatethe Rb pathway in STAT5A-induced senescence. JBiol Chem. 2007; 282:34938-44. https://doi.org/10.1074/jbc.M707074200
51. Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, etal. A transcriptome profile in hepatocellularcarcinomas based on integrated analysis ofmicroarray studies. Diagn Pathol. 2017; 12:4.https://doi.org/10.1186/s13000-016-0596-x
52. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis ofcomplex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1. https://doi.org/10.1126/scisignal.2004088
53. Li B, Dewey CN. RSEM: accurate transcriptquantification from RNA-Seq data with or without areference genome. BMC Bioinformatics. 2011;12:323. https://doi.org/10.1186/1471-2105-12-323